Cohance Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company, for the Quarter and Half year ended 30 September 2026

26 October 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Intimation of Board Meeting of the Company Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that a meeting of the Board of Directors of the Company will be held on Friday, 6 November 2026, inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half-year ended 30 September 2026. Further, in continuation to our letter dated 28 September 2026 regarding closure of Trading Window for dealing in the shares of the Company for Designated Persons and their immediate relatives, the Trading Window shall remain closed until 9 November 2026. Kindly take the above information record. Thanking you Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer